Ibuzatrelvir (PF-07817883) Oral Antiviral
COVID-19 treatment in high-risk non-hospitalised adults
Sponsor: Pfizer
- N/AEnrollment target
- 95Trial sites
- 4Countries
- October 2027Est. completion
- NCT06679140Registry record
About this trial
Second-generation oral protease inhibitor intended to treat COVID-19 without the ritonavir boosting that drives Paxlovid's drug-drug interactions.
Primary endpoints
- Time to sustained alleviation of COVID-19 symptoms
Latest update
August 2026
The Phase 3 record for ibuzatrelvir was refreshed showing the study still recruiting with no results posted. Pfizer's earlier intravenous candidate PF-07304814 (lufotrelvir), which this tracker previously listed as a pan-coronavirus vaccine, remains discontinued.
SourceTrial information is compiled from public sources and may be out of date. It is not medical advice and is not an offer of enrolment; check the registry entry or speak to a physician before acting on it.